{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:06:15Z","timestamp":1792872375146,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.esmoop.2025.105808","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:23:56Z","timestamp":1759548236000},"page":"105808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cyclin-dependent kinase 4\/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)"],"prefix":"10.1016","volume":"10","author":[{"given":"L.F.C.","family":"de Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.O.C.","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Cappellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Batalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105808_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105808_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10549-011-1616-x","article-title":"Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger","volume":"130","author":"Gaudet","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105808_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijrobp.2020.08.038","article-title":"Breast cancer molecular subtype as a predictor of radiation therapy fractionation sensitivity","volume":"109","author":"Lalani","year":"2021","journal-title":"Int J Radiat Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105808_bib4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.esmoop.2025.105808_bib5","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105808_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251353623","article-title":"Understanding and overcoming CDK4\/6 inhibitor resistance in HR+\/HER2\u2212 metastatic breast cancer: clinical and molecular perspectives","volume":"17","author":"da Silva","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105808_bib7","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105808_bib8","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-22-3843","article-title":"Clinical and genomic characteristics of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer following progression on cyclin-dependent kinase 4 and 6 inhibitors","volume":"29","author":"Rao","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105808_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914427","article-title":"Progression after first-line cyclin-dependent kinase 4\/6 inhibitor treatment: analysis of molecular mechanisms and clinical data","volume":"24","author":"Villa","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2025.105808_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1272602","article-title":"Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4\/6 inhibitors beyond progression","volume":"13","author":"Horani","year":"2023","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105808_bib11","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2\u2212 metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105808_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1408664","article-title":"Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4\/6 inhibitors progression - real-world data analysis","volume":"14","author":"Kubeczko","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2025.105808_bib13","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.esmoop.2025.105808_bib14","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2025.105808_bib15","article-title":"Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2\u2212 advanced breast cancer following progression on a prior CDK4\/6 inhibitor plus endocrine therapy: primary outcome of the phase 3 postMONARCH trial","volume":"42","author":"Kalinsky","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105808_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/14737140.2024.2346188","article-title":"Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child","volume":"24","author":"Keenan","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"issue":"24","key":"10.1016\/j.esmoop.2025.105808_bib17","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: MAINTAIN trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105808_bib18","first-page":"149","article-title":"Clinical outcomes with abemaciclib after prior CDK4\/6 inhibitor progression in breast cancer: a multicenter experience","volume":"19","author":"Wander","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105808_bib19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105808_bib20","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-020-16559-0","article-title":"Quantifying CDK inhibitor selectivity in live cells","volume":"11","author":"Wells","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105808_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","article-title":"Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity","volume":"26","author":"Hafner","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105808_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","volume":"14","author":"Johnston","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105808_bib23","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","article-title":"Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts","volume":"4","author":"Li","year":"2013","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105808_bib24","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105808_bib25","article-title":"A gene panel associated with abemaciclib utility in ESR1-mutated breast cancer after prior cyclin-dependent kinase 4\/6-inhibitor progression","volume":"7","author":"Brett","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"28","key":"10.1016\/j.esmoop.2025.105808_bib26","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105808_bib27","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2\u2212 metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105808_bib28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105808_bib29","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105808_bib30","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105808_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CMAR.S72592","article-title":"Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options","volume":"7","author":"Harb","year":"2015","journal-title":"Cancer Manag Res"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105808_bib32","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S1470-2045(21)00472-1","article-title":"Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4\/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis","volume":"22","author":"Gao","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105808_bib33","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105808_bib34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105808_bib35","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2017.76.9331","volume":"36","author":"Kornblum","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105808_bib36","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA -mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925016771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925016771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:45:46Z","timestamp":1773107146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925016771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2059702925016771"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105808","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclin-dependent kinase 4\/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105808"}}